PDCD1 and neoplasm: Indeed, 3LL-ΔNRAS tumours were completely refractory to anti-PD-1 and/or anti-CTLA-4, with the exception of one responder in the anti-CTLA-4 group (Fig. 4a and Supplementary Fig. 4a).